Company
TQ Therapeutics
- Biotech
- Location:
- Planegg, Germany
Description
TQ Therapeutics operates a CELLfinity platform that delivers in vivo cell and gene therapies using a proprietary EXiVO automated approach to retain autologous therapy advantages.
TQ Therapeutics is located in the Munich ecosystem.
Related
CPTxCPTx develops in vivo CAR-T genetic medicines using an immune-silent ssDNA platform and non-viral lipid nanoparticle delivery to encode…
Oxford BiomedicaOxford Biomedica provides end-to-end CDMO services for cell and gene therapy clients, using lentivirus, AAV, and other viral vectors to…
VRG TherapeuticsVRG Therapeutics designs therapeutic miniproteins using a proprietary platform that combines AI-driven protein engineering with wet-lab…
SyngensysSyngensys develops synthetic gene promoters using transcriptional landscape analysis, computational design, selection, and validation to…
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
Prevision MedicinePrevision Medicine tests living cancer and healthy cells from a patient biopsy against 100+ drugs and combinations using a patented ex vivo…
MogrifyMogrify develops platform technologies for direct cellular reprogramming that analyze transcriptomic, gene regulatory, and epigenetic data…
Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
- Asgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…